A Multifactorial Approach for Sarcopenia Assessment: A Literature Review
Open Access
Abstract
Sarcopenia refers to a progressive and generalized weakness of skeletal muscle as individuals age. Sarcopenia usually occurs after the age of 60 years and is associated with a persistent decline in muscle strength, function, and quality. A comparison of the risk factors associated with sarcopenia based on the European Working Group on Sarcopenia (1 and 2) in Older People, the Asian Working Group for Sarcopenia (1 and 2), the International Working Group on Sarcopenia, and the Foundation for the National Institutes of Health revealed no consistent patterns. Accordingly, the identification of a single risk factor for sarcopenia is unpredictable due to its “multifactorial” pathogenesis, with the involvement of a multitude of factors. Therefore, the first aim of this review was to outline and propose that the multiple factors associated with sarcopenia need to be considered in combination in the design of new experimentation in this area. A secondary aim was to highlight the biochemical risk factors that are already identified in subjects with sarcopenia to assist scientists in understanding the biology of the pathophysiological mechanisms affecting the old people with sarcopenia. We also briefly discuss primary outcomes (physical) and secondary outcomes (social and financial) of sarcopenia. For future investigative purposes, this comprehensive review may be useful in considering important risk factors in the utilization of a panel of biomarkers emanating from all pathways involved in the pathogenesis of this disease. This may help to establish a uniform consensus for screening and defining this disease. Considering the COVID-19 pandemic, its impact may be exacerbated in older populations, which requires immediate attention. Here, we briefly suggest strategies for advancing the development of smart technologies to deliver exercise in the COVID-19 era in an attempt regress the onset of sarcopenia. These strategies may also have an impact on sarcopenia’s primary and secondary outcomes.Keywords
This publication has 153 references indexed in Scilit:
- Comparisons of Sarcopenia Defined by IWGS and EWGSOP Criteria Among Older People: Results From the I-Lan Longitudinal Aging StudyJournal of the American Medical Directors Association, 2013
- Plasma heat shock protein 72 as a biomarker of sarcopenia in elderly peopleCell Stress and Chaperones, 2012
- Identification of Novel Genes Involved in Sarcopenia Through RNAi Screening in Caenorhabditis elegansThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2011
- Sarcopenia: An Undiagnosed Condition in Older Adults. Current Consensus Definition: Prevalence, Etiology, and Consequences. International Working Group on SarcopeniaJournal of the American Medical Directors Association, 2011
- Sarcopenia: European consensus on definition and diagnosisAge and Ageing, 2010
- Genome-wide Association and Replication Studies Identified TRHR as an Important Gene for Lean Body MassThe American Journal of Human Genetics, 2009
- Higher circulating levels of uric acid are prospectively associated with better muscle function in older personsMechanisms of Ageing and Development, 2008
- Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and womenOsteoporosis International, 2008
- Carotenoids as protection against sarcopenia in older adultsArchives of Biochemistry and Biophysics, 2007
- Drug Insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and agingNature Clinical Practice Endocrinology & Metabolism, 2006